In a report released yesterday, Liana Moussatos from Wedbush reiterated a Buy rating on Ascendis Pharma (NASDAQ: ASND), with a price target of $79. The company’s shares opened today at $70.98, close to its 52-week high of $76.99.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 1.3% and a 44.4% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Catabasis Pharmaceuticals.
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $82, representing a 15.5% upside. In a report issued on August 29, Stifel Nicolaus also reiterated a Buy rating on the stock with a $81 price target.
.
See today’s analyst top recommended stocks >>
Based on Ascendis Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $27.12 million. In comparison, last year the company had a GAAP net loss of $33.82 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.
